Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Authors: Tünde Vágó, Péter Tóth, Tim Hague, Szilveszter Juhos Introduction: The 1000 Genomes Project (1KG) was the first large-scale sequencing project to obtain comparable whole genome sequences from diverse human populations. Previously we validated our HLA typing method using these datasets for Class-II …more
EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more